NASDAQ · Drug Manufacturers - Specialty & Generic
TKNO (TKNO) Stock
$4.96
+2.16%
NASDAQ: TKNO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026
GlobeNewswire · Jul 22, 2026
May 2026's Promising Penny Stocks To Watch
Simply Wall St. · May 28, 2026
Alpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St. · May 9, 2026
Alpha Teknova Q1 Earnings Call Highlights
MarketBeat · May 7, 2026
Alpha Teknova, Inc. Q1 2026 Earnings Call Summary
Moby · May 7, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held9.32%
Institutions Held84.68%
Institutions Float Held93.39%
Peer Comparison
About TKNO
TKNO is led by CEO Stephen Gunstream, employs 173 people, headquartered in US, publicly traded since 2021.
TKNO stock trades at $4.96 with a market capitalization of $265.66M. The stock is valued at a price-to-earnings (P/E) ratio of -16.86, price-to-book of 3.22, price-to-sales of 5.30. Over the past 52 weeks the stock has ranged between $1.91 and $6.68, and currently trades 25.7% below its 52-week high.
On profitability, TKNO generates a return on equity (ROE) of -23.92%, return on capital employed of -24.64%, an operating margin of -39.02%, a net profit margin of -41.07%.